Prescription Fills Among Patients With Type 2 Diabetes After Hospitalization for Acute Coronary Syndrome.
急性冠狀動脈綜合症住院後2型糖尿病患者的處方藥填寫情況。
JAMA Netw Open 2024-11-27
Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study.
Semaglutide 與非酒精性脂肪肝疾病及第二型糖尿病患者不良肝臟結果風險的關聯:一項多機構隊列研究。
Hepatol Int 2024-11-27
SGLT2 inhibitors in the prevention of diabetic cardiomyopathy: Targeting the silent threat.
SGLT2 抑制劑在預防糖尿病性心肌病中的應用:針對這一隱形威脅。
World J Cardiol 2024-11-27
Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes in Patients with Acute Coronary Syndrome and Type 2 Diabetes.
鈉-葡萄糖共轉運蛋白 2 抑制劑對急性冠狀動脈綜合症及 2 型糖尿病患者心血管結果的影響。
Diabetes Metab Syndr Obes 2024-11-27
Sodium-Glucose Cotransporter 2 Inhibitors Improve Body Composition by Increasing the Skeletal Muscle Mass/Fat Mass Ratio in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.
鈉-葡萄糖共轉運蛋白 2 抑制劑透過增加骨骼肌質量/脂肪質量比改善 2 型糖尿病患者的身體組成:一項 52 週的前瞻性實際研究。
Nutrients 2024-11-27
Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update.
心衰竭糖尿病患者中鈉-葡萄糖共轉運蛋白-2抑制劑的最新進展。
Pharmaceuticals (Basel) 2024-11-27
Glucometabolic Efficacy of the Empagliflozin/Metformin Combination in People with Type 1 Diabetes and Increased Cardiovascular Risk: A Sub-Analysis of a Pilot Randomized Controlled Trial.
Empagliflozin/Metformin 组合在1型糖尿病及心血管风险增加人群中的葡萄糖代谢疗效:一项初步随机对照试验的子分析。
J Clin Med 2024-11-27
Proteinuria and Progression of Renal Damage: The Main Pathogenetic Mechanisms and Pharmacological Approach.
蛋白尿與腎損傷進展:主要的病理生理機制及藥物治療方法。
Medicina (Kaunas) 2024-11-27